Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.
Objective: Objective: In order to improve the understanding of the alpha-synuclein system and its role in Parkinson’s disease, Elan and Rosa collaborated in the development…Parkinson’s Disease Medications Availability in Each Philippine Region
Objective: This study aimed to enumerate the different Parkinson’s disease medications in the Philippines and describe the distribution and availability among the 17 regions of…Determinant factors of treatment adherence in Parkinson’s disease
Objective: To determine factors predicting treatment adherence in patients with idiopathic Parkinson’s disease. Background: Parkinson’s disease is the second most common cause of neurodegenerative disease…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment
Objective: To assess the safety and efficacy of carbidopa/levodopa enteral suspension (CLES) in Parkinson’s disease (PD) patients with cognitive impairment. Background: As Parkinson’s Disease progresses,…Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study
Objective: To determine the long-term outcomes of levodopa/carbidopa intestinal gel infusion (LCIG) in advanced Parkinson's disease (PD) patients. Background: LCIG was introduced in the Netherlands…The impact of STN DBS on kinetic tremor in Parkinson’s disease patients
Objective: The aim of the study is to evaluate the impact of STN DBS on kinetic tremor in PD patients in comparison to pharmacologically treated…Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study
Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease
Objective: (1) To reassess the behavioral impact of novel noradrenergic (atomoxetine) and serotonergic (citalopram) therapies for impulsivity and (2) to develop predictive models to identify…Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease
Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- Next Page »